Anixa Biosciences, Inc. (ANIX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-01-12
How it makes money
Large pharmaceutical companies pay for its technology through licensing agreements.
It does not currently generate revenue from its therapeutics or vaccines. It aims to license these technologies to large pharmaceutical companies that have the infrastructure to manufacture and market products.
What protects it: the moat
It relies on exclusive, royalty-bearing licenses for its core technology.
It holds an exclusive worldwide license for its CAR-T technology through its subsidiary, Certainty.
What growth costs
Research and development expenses totaled $5,071,000 in fiscal year 2025.
It must reinvest in research and development for its cancer vaccine and CAR-T therapeutics programs.
What could damage it
Inadequate working capital could stop its ability to fund clinical trials.
If the company cannot raise more funds, it may lack the resources to complete the expensive process of obtaining FDA approvals.
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.